Representative’s Warrant AgreementPolyrizon Ltd. • October 7th, 2022 • Pharmaceutical preparations
THIS WARRANT TO PURCHASE ORDINARY SHARES(the “Warrant”) certifies that, for value received, Aegis Capital Corp., or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ ], 2022 (the “Initial Exercise Date”)3 and prior to [ ], 2027 at 5:00 p.m. (New York time) (the “Termination Date”)4 but not thereafter, to subscribe for and purchase from POLYRIZON LTD., an Israeli company (the “Company”), up to [ ]ordinary shares par value NIS 0.04 per share (the “Ordinary Shares”), of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 7th, 2022 • Polyrizon Ltd. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of , 20 , is entered into by and between Polyrizon Ltd., an Israeli company whose address is 5 Hatidhar St, Raanana, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page hereto officer (the “Indemnitee”).
Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosedAgreement • October 7th, 2022 • Polyrizon Ltd. • Pharmaceutical preparations
This Agreement (the “Agreement”) is made and entered into this 7th day of June 2022 (“Effective Date”) by and between Polyrizon Ltd., Company Number 513637025 located at 5 Hatidhar St. R’annana, Israel. (“Polyrizon”), and NurExone Biologic Ltd., Company No. 516209202 located at 9 Mezada St., Bney Brak, Israel (“Nurexone”). (collectively referred to as “Parties” and each may be referred individually as a “Party”).
Certain confidential information contained in this document, marked by brackets and asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly...Agreement • October 7th, 2022 • Polyrizon Ltd. • Pharmaceutical preparations
This Agreement (the “Agreement”) is made and entered into this 30th day of May, 2022 (“Effective Date”) by and between Polyrizon Ltd., Company Number 513637025 located at 5 Hatidhar St. R’annana, Israel. (“Polyrizon”), and SciSparc Ltd., Company No. 513581652 located at 20 Raul Walenberg St., Tel Aviv, Israel (“SciSparc”). (Collectively referred to as “Parties” and each may be referred individually as a “Party”).
